Dyuti Majumdar

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Novartis Ag, Bayer Pharmaceuticals Corporation, Bayer Healthcare LLC. Active years: 2007-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dyuti Majumdar. Retrieved from https://idiyas.com/inventor/dyuti-majumdar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 28.6

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 10.1

ph-index = 2

Forward Citations = 10(Granted Patents)

Location History:

Milford, CT (US) (2007)
Cambridge, MA (US) (2010 - 2024)

Company Filing History:

Bayer Pharmaceuticals Corporation

Years Active: 2007-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11905283 - Compounds and compositions for inhibiting the activity of SHP2 (2024-02-20),

2. 10934285 - Compounds and compositions for inhibiting the activity of SHP2 (2021-03-02),

3. 8349883 - Hydroxamate-based inhibitors of deacetylases B (2013-01-08),

4. 7943652 - Hydroxamate-based inhibitors of deacetylases B (2011-05-17),

5. 7906653 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation (2011-03-15),

6. 7714004 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation (2010-05-11),

7. 7265144 - Anilinopyrazole derivatives useful for the treatment of diabetes (2007-09-04),

Title: **Dyuti Majumdar: Innovator in Pharmaceutical Compounds**

Introduction

Dyuti Majumdar is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of pharmaceuticals. With seven patents to his name, he has been instrumental in developing compounds that target specific biological processes, particularly those related to the inhibition of SHP2 activity.

Latest Patents

One of Dyuti Majumdar's latest patents focuses on "Compounds and compositions for inhibiting the activity of SHP2." This invention details compounds defined by a specific formula that are capable of inhibiting SHP2, which is crucial in various disease management strategies. The patent also outlines a process for the preparation of these compounds, along with pharmaceutical preparations that incorporate them and methods of using these innovations to address disorders associated with aberrant SHP2 activity.

Career Highlights

Throughout his career, Dyuti has contributed to leading pharmaceutical companies, including Novartis AG and Bayer Pharmaceuticals Corporation. His work in these organizations has allowed him to explore and innovate within the realm of pharmaceutical research and development, further establishing his reputation as an inventor.

Collaborations

Dyuti Majumdar has collaborated with notable colleagues in the industry, including Joachim Rudolph and Louis-David Cantin. These partnerships have facilitated the exchange of ideas and expertise, driving forward the advancements in his research projects and fostering innovative solutions.

Conclusion

Dyuti Majumdar exemplifies the impact inventors can have in the pharmaceutical industry through targeted innovations. His patents continue to shape the landscape of drug development, underscoring the importance of research and collaboration in addressing complex medical challenges.

Profile summary based on public USPTO records.